Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global pharmaceutical company, received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility in Goa, India. The facility received a Voluntary Action Indicated (VAI) classification following the inspection.
Inspection Conducted in June 2026
The U.S. FDA conducted the inspection at Glenmark’s Goa manufacturing facility from June 22 to June 30, 2026. Subsequently, the regulatory authority issued the EIR with a VAI status for the facility. As per the press release, the development provides an update on the regulatory status of Glenmark’s Goa formulations manufacturing operations following the U.S. FDA inspection.
